ESSA Pharma (EPIX) announces that its Securityholders have approved the acquisition of all of the issued and outstanding common shares of the Company by XenoTherapeutics Inc., a non-profit biotechnology company, by way of a statutory plan of arrangement at the special meeting of Securityholders held today.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPIX:
- ESSA Pharma Faces Class Action Lawsuit in California
- ESSA Pharma Receives Court Approval for Acquisition
- Essa Pharma provides update on combination agreement with Xeno
- ESSA Pharma Amends Agreement with XenoTherapeutics, Adjusts Shareholder Terms
- Essa Pharma amends business combination agreement with XenoTherapeutics